Bioprinting Market Report 2026

The bioprinting market size has grown rapidly in recent years. It will grow from $2.73 billion in 2025 to $3.27 billion in 2026 at a compound annual growth rate (CAGR) of 19.8%. The growth in the historic period can be attributed to rising demand for tissue reconstruction, increasing need for organ transplants, growing chronic disease burden, shortage of donor organs, and rising aging population.

The bioprinting market size is expected to see rapid growth in the next few years. It will grow to $6.68 billion in 2030 at a compound annual growth rate (CAGR) of 19.5%. The growth in the forecast period can be attributed to increasing demand for regenerative medicine, expanding applications in drug testing and development, growing R&D investments, rising prevalence of chronic diseases, and growing interest in personalized medicine. Major trends in the forecast period include technological advancements in bioprinting hardware, innovations in bioinks and biomaterials, development of customized 3D tissue and organ models, increased use in pharmaceutical drug development and testing, and growth of public-private research collaborations in biofabrication.

The growing demand for personalized medicine is expected to drive the expansion of the bioprinting sector in the coming years. Personalized medicine is a healthcare approach that customizes treatments for individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and enhance care. This demand is rising due to advancements in genomic technologies, which allow for accurate identification of genetic variations and development of tailored treatments for patients. Bioprinting supports personalized medicine by facilitating the creation of patient-specific tissues and organ models aligned with individual biological profiles. It enhances treatment accuracy by enabling customized drug testing, regenerative therapies, and improved prediction of patient responses. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from 12 approvals in 2022. Consequently, the rising demand for personalized medicine is fueling the growth of the bioprinting sector.

Leading companies in the bioprinting sector are concentrating on creating advanced resin materials, such as polyester-based volumetric bioprinting resins, to facilitate the rapid production of complex tissue constructs with high resolution and biocompatibility. Polyester-based volumetric bioprinting resins are engineered to form complete three-dimensional structures in a single step rather than layer-by-layer, enabling the development of intricate tissue models for regenerative medicine and tissue engineering studies. For example, in May 2025, BIO INX, a Belgium-based bioink technology firm, and Readily3D, a Switzerland-based bioprinter developer, introduced READYPCL INX, a polyester-based resin that allows high-speed volumetric printing with resolutions as precise as 100 µm. The resin delivers strong mechanical performance, full biodegradability, and ISO 10993‑5 biocompatibility, making it ideal for complex bone and cartilage applications. This introduction marks a notable advancement in bioprinting technology by combining speed, accuracy, and biocompatibility to support next-generation tissue engineering and regenerative medicine research.

In November 2024, Bio‑INX GmbH, a Germany‑based biofabrication and 3D bioprinting technology company, formed a partnership with Carl Roth GmbH + Co. KG to broaden access to 3D bioprinting solutions for life‑science researchers. Through this collaboration, Bio‑INX GmbH and Carl Roth GmbH + Co. KG intend to integrate Bio‑INX’s advanced 3D bioprinting hardware and bioinks with Carl Roth’s comprehensive portfolio of cell culture reagents, biomaterials, and laboratory consumables to facilitate scalable adoption of bioprinting workflows across academic, pharmaceutical, and biotech laboratories. Carl Roth GmbH + Co. KG is a Germany‑based supplier of laboratory chemicals and bioprocessing solutions.

Major companies operating in the bioprinting market are GeSiM GmbH, Poietis SAS, Stratasys Ltd., BICO Group AB, Cyfuse Biomedical K.K., Inventia Life Science Pty Ltd., Aspect Biosystems Ltd., CollPlant Biotechnologies Ltd., Pandorum Technologies Pvt. Ltd., ROKIT Healthcare Inc., Prellis Biologics Inc., 3D Systems Corporation, RegenHU Ltd., REGEMAT 3D S.L., 3DBio Therapeutics Inc., Brinter Ltd., Allevi Inc., Next Big Innovation Labs, Precise Bio Inc., TissueLabs Inc., Fluicell AB, XLife Sciences, Organovo Holdings Inc.

North America was the largest region in the bioprinting market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioprinting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioprinting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have impacted the bioprinting market by increasing costs of imported 3D bioprinters, bioinks, and specialized biomaterials, creating challenges for manufacturers and research institutions. the tariffs particularly affect high-tech equipment segments and regions such as north america and europe that rely on imports for advanced bioprinting components. while tariffs raise production expenses, they also encourage local manufacturing, innovation in cost-effective bioinks, and domestic supply chain development, potentially driving more resilient and self-sufficient market growth.

Bioprinting is a cutting-edge technique that utilizes 3D-printing methods to fabricate biological structures using living cells and biomaterials. It allows for the creation of tissues or tissue-like constructs with precise and controlled architecture. This technology is designed to mimic biological functions for applications including tissue modeling, regenerative research, and experimental studies.

The main products in bioprinting include 3D bioprinters, bioinks, and 3D bioprinted products and services. 3D bioprinters are specialized machines that use layer-by-layer printing processes to build biological structures using living cells and biomaterials. Materials include living cells, hydrogels, extracellular matrices, biomaterials, and others. Technologies include inkjet bioprinting, extrusion bioprinting, laser-assisted bioprinting, magnetic levitation bioprinting, and others. Applications include tissue engineering, regenerative medicine, drug development, research, and others, with key end users including academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and others.

The bioprinting market consists of revenues earned by entities by providing services such as custom tissue fabrication, research and development support, bioprinting design and modeling, cell and bioink optimization services, and prototyping for regenerative medicine and drug testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprinting market also includes sales of bioprinters, bioinks, living cells and biomaterials, software platforms, and bioprinting accessories and consumables. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.